Serko First Half 2023 Earnings: NZ$0.17 loss per share (vs NZ$0.14 loss in 1H 2022)




  • In Business
  • 2022-11-25 18:11:00Z
  • By Simply Wall St.
 

Serko (NZSE:SKO) First Half 2023 Results

Key Financial Results

  • Revenue: NZ$18.8m (up 115% from 1H 2022).

  • Net loss: NZ$19.7m (loss widened by 30% from 1H 2022).

  • NZ$0.17 loss per share (further deteriorated from NZ$0.14 loss in 1H 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Serko Earnings Insights

Looking ahead, revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Software industry in Oceania.

Performance of the market in New Zealand.

The company's shares are down 3.8% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 2 warning signs for Serko that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You'll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

COMMENTS

More Related News

The past year for Oxford Biomedica (LON:OXB) investors has not been profitable
The past year for Oxford Biomedica (LON:OXB) investors has not been profitable

Oxford Biomedica plc ( LON:OXB ) shareholders should be happy to see the share price up 26% in the last quarter. But...

DBS Group Holdings (SGX:D05) Ticks All The Boxes When It Comes To Earnings Growth
DBS Group Holdings (SGX:D05) Ticks All The Boxes When It Comes To Earnings Growth

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

TAT Technologies (NASDAQ:TATT) shareholders have endured a 41% loss from investing in the stock five years ago
TAT Technologies (NASDAQ:TATT) shareholders have endured a 41% loss from investing in the stock five years ago

TAT Technologies Ltd. ( NASDAQ:TATT ) shareholders should be happy to see the share price up 12% in the last month. But...

Investing in Intapp (NASDAQ:INTA) a year ago would have delivered you a 53% gain
Investing in Intapp (NASDAQ:INTA) a year ago would have delivered you a 53% gain

The simplest way to invest in stocks is to buy exchange traded funds. But investors can boost returns by picking...

Investors in Bicycle Therapeutics (NASDAQ:BCYC) have made a impressive return of 157% over the past three years
Investors in Bicycle Therapeutics (NASDAQ:BCYC) have made a impressive return of 157% over the past three years

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business